-
SAB2104368-100UL
ANTI-ATXN2 (C15-1744-584)
Price: $1,032.85List Price: $1,147.61Immunogen Synthetic peptide directed towards the middle region of human ATXN2 Biochem/physiol Actions The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive -
SAB2104138-100UL
ANTI-ATXN7
Price: $980.46List Price: $1,089.40Immunogen Synthetic peptide directed towards the middle region of human ATXN7 Biochem/physiol Actions ATXN7 is involved in neurodegeneration. ATXN7 acts as component of the STAGA transcription coactivator-HAT complex. -
M339661-100mg
Methsuximide (C09-0963-070)
Price: $553.07List Price: $614.53ApplicationMethsuximide is a succinimide with anti-epileptic and anti-convulsant properties. -
M339661-500mg
Methsuximide (C09-0963-071)
Price: $2,248.71List Price: $2,498.57ApplicationMethsuximide is a succinimide with anti-epileptic and anti-convulsant properties. -
M339661-50mg
Methsuximide (C09-0963-072)
Price: $307.49List Price: $341.66ApplicationMethsuximide is a succinimide with anti-epileptic and anti-convulsant properties. -
19058-10
Methsuximide-10 mg
Price: $128.45List Price: $142.72A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials. -
19058-100
Methsuximide-100 mg
Price: $576.37List Price: $640.42A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials. -
19058-25
Methsuximide-25 mg
Price: $267.09List Price: $296.76A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials. -
19058-50
Methsuximide-50 mg
Price: $376.35List Price: $418.17A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials. -
M345476-1mg
Methsuximide-d5 (C09-0964-027)
Price: $369.53List Price: $410.59Application:A labelled calcium channel succinimide antiepileptic drug. Anticonvulsant. -
M345476-5mg
Methsuximide-d5 (C09-0964-028)
Price: $1,560.28List Price: $1,733.65Application:A labelled calcium channel succinimide antiepileptic drug. Anticonvulsant. -
SML3325-5MG
SOB-AM2 (C15-1720-965)
Price: $230.46List Price: $256.06General description Sob-AM2 is a methyl amide derivative and a central nervous system (CNS)- selective prodrug of Sobetirome. Even in the absence of monocarboxylate transporter 8 (Mct8), Sob-AM2 can penetrate the brain and exhibit thyromimetic